|
|||
2010-02-23 15:30:00 CET 2010-02-23 15:30:49 CET REGULATED INFORMATION Biotie Therapies - Company AnnouncementBiotie will publish its Financial Statement Release for 1 January ‑ 31 December 2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish timeBIOTIE THERAPIES CORP. STOCK EXCHANGE ANNOUNCEMENT 23 February 2010 at 4.30 p.m. Biotie will publish its Financial Statement Release for 1 January ‑ 31 December 2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time. The webcast and conference call will be arranged on the publishing day at 1.00 p.m Finnish time (12.00 noon CET, 11.00 a.m UK time), and will also be available as live audio webcast at www.biotie.com. The call will be held in English. The Financial Statement Release will be presented by President and CEO Timo Veromaa. Callers may access the conference directly at the following telephone numbers: UK: +44 (0) 203 003 2666, Finland: 0800 914672, no code. Lines are to be reserved ten minutes before the start of conference call. An on-demand audiocast of the conference will also be published on Biotie's website later during the day. Biotie publishes financial information in English and Finnish. All releases are posted in full on Biotie's website as soon as they are published. Turku, February 23, 2010 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com<mailto:virve.nurmi@biotie.com> Distribution: NASDAQ OMX Helsinki Ltd Main Media Biotie Therapies Corp. Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany. Biotie shares are listed on NASDAQ OMX Helsinki Ltd. For more information, please refer to www.biotie.com [HUG#1387519] |
|||
|